<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">jotci</journal-id>
			<journal-title-group>
				<journal-title>Revista Brasileira de Cardiologia Invasiva</journal-title>
				<abbrev-journal-title abbrev-type="publisher">J Transcat Intervent</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0104-1843</issn>
			<issn pub-type="epub">2179-8397</issn>
			<publisher>
				<publisher-name>Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista - SBHCI</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.31160/JOTCI202331A20230009</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>ORIGINAL ARTICLE</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Initial experience with the Expressman™ guide catheter extension in a high-volume tertiary cardiology center</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3383-5365</contrib-id>
					<name>
						<surname>Silveira</surname>
						<given-names>Eduardo</given-names>
					</name>
					<role>Conception and design of the study</role>
					<role>data collection</role>
					<role>text writing</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4198-2621</contrib-id>
					<name>
						<surname>Slaviero</surname>
						<given-names>João Vitor</given-names>
					</name>
					<role>Conception and design of the study</role>
					<role>data collection</role>
					<role>text writing</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9620-2429</contrib-id>
					<name>
						<surname>Azmus</surname>
						<given-names>Alexandre</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0002-1675-9911</contrib-id>
					<name>
						<surname>Moraes</surname>
						<given-names>Cláudio Vasques de</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3799-098X</contrib-id>
					<name>
						<surname>Teixeira</surname>
						<given-names>Julio Vinicius</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9674-8528</contrib-id>
					<name>
						<surname>Leite</surname>
						<given-names>Rogério Sarmento</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0006-8686-4476</contrib-id>
					<name>
						<surname>Manica</surname>
						<given-names>André</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9698-1787</contrib-id>
					<name>
						<surname>Gomes</surname>
						<given-names>Henrique</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Moraes</surname>
						<given-names>Claudio</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0001-7099-830X</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Eduardo</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0415-1020</contrib-id>
					<name>
						<surname>Teixeira</surname>
						<given-names>Julia Kurtz</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5018-9989</contrib-id>
					<name>
						<surname>Fuchs</surname>
						<given-names>Felipe</given-names>
					</name>
					<role>approval of the final version to be published</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9027-0623</contrib-id>
					<name>
						<surname>Piccaro</surname>
						<given-names>Pedro</given-names>
					</name>
					<role>Conception and design of the study</role>
					<role>data interpretation</role>
					<role>text writing</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3192-8835</contrib-id>
					<name>
						<surname>Quadros</surname>
						<given-names>Alexandre Schaan de</given-names>
					</name>
					<role>Conception and design of the study</role>
					<role>data interpretation</role>
					<role>text writing</role>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				<institution content-type="orgname">Instituto de Cardiologia do Rio Grande do Sul</institution>
				<addr-line>
					<named-content content-type="city">Porto Alegre</named-content>
					<named-content content-type="state">RS</named-content>
				</addr-line>
				<country country="BR">Brazil</country>
				<institution content-type="original"> Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil.</institution>
			</aff>
			<author-notes>
				<corresp id="c01"><bold>Corresponding author:</bold> Alexandre Quadros. Instituto de Cardiologia/Fundação Universitária de Cardiologia. Avenida Princesa Isabel, 395 − Santana. Zip code: 90620-001 − Porto Alegre, RS, Brazil. E-mail: <email>consult.asq@gmail.com</email>
				</corresp>
				<fn fn-type="conflict">
					<p>CONFLICTS OF INTEREST</p>
					<p>This study was funded by APT Medical.</p>
				</fn>
			</author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>02</day>
				<month>10</month>
				<year>2023</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2023</year>
			</pub-date>
			<volume>31</volume>
			<elocation-id>eA20230009</elocation-id>
			<history>
				<date date-type="received">
					<day>19</day>
					<month>06</month>
					<year>2023</year>
				</date>
				<date date-type="accepted">
					<day>17</day>
					<month>09</month>
					<year>2023</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
				</license>
			</permissions>
			<abstract>
				<title>ABSTRACT</title>
				<sec>
					<title>Background</title>
					<p> Guide catheter extensions provide increased support in complex percutaneous coronary interventions. The Expressman™ is a novel guide catheter extension and the objective was to assess the impact of its use on procedural success and complications in a high-volume reference center.</p>
				</sec>
				<sec>
					<title>Methods</title>
					<p> We analyzed data from all consecutive procedures in which the Expressman™ guide catheter extension was used. The decision to use a guide catheter extension was at operator’s discretion. Device success was defined as the successful positioning of the guide catheter extension in the coronary vessel and procedural success was defined as &lt;20% residual stenosis and TIMI 3 flow, with no loss of significant side branches. Major adverse cardiac and cerebrovascular events were defined as the composite of all-cause death, myocardial infarction, target vessel revascularization and stroke.</p>
				</sec>
				<sec>
					<title>Results</title>
					<p> From April 2022 to January 2023, 34 procedures were included. The majority of the patients were male (59%) and the mean age was 66.5 years. Guide catheter extension use was not planned pre-procedure in 17 procedures (50%). The most common reasons for guide catheter extension use were target vessel angulation or tortuosity and unfavorable coronary ostium position. Device success was obtained in 88% and revascularization success in 91%. There were three side branch occlusions. During in-hospital clinical follow-up, no major adverse cardiac and cerebrovascular events or major bleeding occurred.</p>
				</sec>
				<sec>
					<title>Conclusion</title>
					<p> The device success and procedural success were high and the rate of complications was low. Guide catheter extension use as bailout technique in complex anatomies allowed procedural success in the vast majority of otherwise untreatable patients.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="en">
				<kwd>Percutaneous coronary intervention</kwd>
				<kwd>Cardiac catheters</kwd>
				<kwd>Coronary artery diseases</kwd>
				<kwd>Equipment design</kwd>
				<kwd>Treatment outcome</kwd>
			</kwd-group>
			<counts>
				<fig-count count="2"/>
				<table-count count="6"/>
				<equation-count count="0"/>
				<ref-count count="10"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>Patients undergoing complex percutaneous coronary interventions (PCI) more frequently present adverse clinical and angiographic features, such as advanced age, increased vessel tortuosity and extensive calcification. To achieve procedural success in those complex situations, guide catheter extensions (GCEs) have been increasingly used.<sup><xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref></sup> These devices allow deep seating within the coronary artery, providing increased support for guidewire and microcatheter advancement, and improving deliverability of balloons and stents.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Guide catheter extensions may also allow selective visualization of the vessel and improve the stability of the guide catheter. Despite all those theoretical benefits and experience of interventional cardiologists, there are still relatively few published data addressing the use of these devices. The Expressman™ GCE is a novel guide extension featuring side holes near the tip, designed to ensure antegrade blood flow and diminish coronary ischemia, a possible complication of deep intubation with these devices.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Also, it has a long exchange segment (35cm) to facilitate stent delivery with less resistance.</p>
			<p>The objective of the present study was to determine the impact of the Expressman™ GCE on procedural success, complication rates and in-hospital outcomes in patients undergoing complex PCI.</p>
		</sec>
		<sec sec-type="methods">
			<title>METHODS</title>
			<sec>
				<title><italic><bold>Study population</bold></italic></title>
				<p>All consecutive procedures with an indication for a GCE use in the period of April 2022 to January 2023 were considered for inclusion. The inclusion criteria were age greater than 18 years and written informed consent. There were no clinical or angiographic exclusion criteria, and the decision to use a GCE was at operator´s discretion.</p>
			</sec>
			<sec>
				<title>Data collection</title>
				<p>Investigators added PCI data to an on-line platform available via Research Electronic Data Capture (REDCap). All investigators received standardized instructions for data entry in REDCap, and clinical, procedural and angiographic information, in addition to post-procedural clinical outcomes were collected on the same platform.</p>
			</sec>
			<sec>
				<title>Definitions</title>
				<p>Technical success of the PCI was defined as successful revascularization within the treated segment and restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow with &lt;20% residual stenosis and without significant side branch occlusion.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> A significant side branch was defined as one supplying the left ventricle with 1.5mm in diameter or larger. Proximal tortuosity was defined as mild (up to one curve with 70°), moderate (two curves with more than 70° or one with 90°) or severe (more than two curves with 70° or more than one curve with 90°).<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Procedural success was defined as achievement of technical success with no in-hospital major adverse cardiac and cerebrovascular events (MACCE), and device success was defined as the successful positioning of the GCE within the coronary vessel, so that it achieved the intended use by the operator.</p>
			</sec>
			<sec>
				<title>Outcomes</title>
				<p>The primary endpoint of the study was procedural success of the index PCI. Secondary endpoints were in-hospital MACCE and procedural complications. Major adverse cardiac and cerebrovascular events included all-cause death, myocardial infarction (MI) and stroke. Myocardial infarction was defined using the fourth universal definition of MI (type 4a).<sup><xref ref-type="bibr" rid="B8">8</xref></sup> Stroke was defined as a new focal neurological deficit of sudden onset of presumably cerebrovascular irreversible cause (or resulting in death) within 24 hours and not associated with any other easily identifiable cause.</p>
				<p>Procedural complications included major bleeding, coronary perforation, cardiac tamponade and urgent revascularization with PCI or coronary artery bypass graft (CABG). Major bleeding was defined as any bleeding causing a reduction in hemoglobin &gt;3g/dL, bleeding requiring transfusion or surgical intervention.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> Coronary perforation was reported and classified according to the Ellis classification.<sup><xref ref-type="bibr" rid="B10">10</xref></sup></p>
			</sec>
			<sec>
				<title>Statistical analysis</title>
				<p>Categorical data was presented as numbers and percentages, while continuous variables as mean ± standard deviation or median [range]. Since this is an observational study with no control group, no further statistical analysis was presented.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<sec>
				<title>Baseline clinical characteristics</title>
				<p>From April 2022 to January 2023, 34 consecutive procedures with the Expressman™ GCE were included in the database. The mean age was 65 years, diabetes mellitus was present in half of the patients, and most of them had dyslipidemia and hypertension (<xref ref-type="table" rid="t1">Table 1</xref>). Past history of myocardial infarction and previous PCI was referred by half of the patients, and a heart failure diagnosis was present in one out of ten individuals. The majority of the procedures were performed in the setting of acute coronary syndrome (ACS).</p>
				<p>
					<table-wrap id="t1">
						<label>Table 1</label>
						<caption>
							<title>Baseline characteristics of the study patients</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup width="50%">
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Clinical characteristics</th>
									<th align="left" style="font-weight:normal"> </th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Age</td>
									<td align="center">65±9.4</td>
								</tr>
								<tr>
									<td>Male sex</td>
									<td align="center">20 (58.8)</td>
								</tr>
								<tr>
									<td>BMI</td>
									<td align="center">27.4 [26.2-29.4]</td>
								</tr>
								<tr>
									<td>Hypertension</td>
									<td align="center">33 (97.1)</td>
								</tr>
								<tr>
									<td>Diabetes</td>
									<td align="center">16 (47.1)</td>
								</tr>
								<tr>
									<td>Dyslipidemia</td>
									<td align="center">32 (94.1)</td>
								</tr>
								<tr>
									<td>PVD</td>
									<td align="center">4 (11.8)</td>
								</tr>
								<tr>
									<td>Family History of CAD</td>
									<td align="center">1 (2.9)</td>
								</tr>
								<tr>
									<td>Smoking (current)</td>
									<td align="center">14 (41.2)</td>
								</tr>
								<tr>
									<td>Previous MI</td>
									<td align="center">16 (47.1)</td>
								</tr>
								<tr>
									<td>Previous PCI</td>
									<td align="center">16 (47.1)</td>
								</tr>
								<tr>
									<td>Previous CABG</td>
									<td align="center">6 (17.6)</td>
								</tr>
								<tr>
									<td>Previous stroke</td>
									<td align="center">2 (5.9)</td>
								</tr>
								<tr>
									<td>Heart failure</td>
									<td align="center">4 (11.8)</td>
								</tr>
								<tr>
									<td>Chronic kidney disease</td>
									<td align="center">2 (5.9)</td>
								</tr>
								<tr>
									<td>ACS</td>
									<td align="center">28 (82.4)</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN1">
								<p>Results expressed as mean ± standard deviation, n (%) or median [range].</p>
							</fn>
							<fn id="TFN2">
								<p>BMI: body mass index; PVD: peripheral vessel disease; CAD: coronary artery disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; ACS: acute coronary syndrome.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>
					<xref ref-type="table" rid="t2">Table 2</xref> shows the angiographic and procedural characteristics of the study patients. The left anterior descending and the right coronary arteries were the most common target vessels, and most procedures were performed through the radial artery. A chronic total occlusion as the target lesion occurred in 12% of the cases, and just one procedure was done with adjunctive use of rotational atherectomy. In half of the cases, GCE use was planned upfront; in the remaining, GCE was used as a bailout after the operator facing technical issues to complete the procedure. The main reasons for GCE use were vessel angulation, proximal vessel tortuosity, and unfavorable coronary ostium position. Microcatheters and intravascular ultrasound (IVUS) were infrequently used.</p>
				<p>
					<table-wrap id="t2">
						<label>Table 2</label>
						<caption>
							<title>Angiographic and procedural characteristics of the study patients</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup width="50%">
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Procedural characteristics</th>
									<th align="left" style="font-weight:normal"> </th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Radial access</td>
									<td align="center">21 (61.8)</td>
								</tr>
								<tr>
									<td>Rotational atherectomy</td>
									<td align="center">1 (2.9)</td>
								</tr>
								<tr>
									<td>Target vessel</td>
									<td> </td>
								</tr>
								<tr>
									<td>Left main coronary artery</td>
									<td align="center">1 (2.9)</td>
								</tr>
								<tr>
									<td>Left anterior descending artery</td>
									<td align="center">12 (35.3)</td>
								</tr>
								<tr>
									<td>Circumflex artery</td>
									<td align="center">8 (23.5)</td>
								</tr>
								<tr>
									<td>Right coronary artery</td>
									<td align="center">12 (35.3)</td>
								</tr>
								<tr>
									<td>CTO</td>
									<td align="center">4 (11.8)</td>
								</tr>
								<tr>
									<td>GCE use planned before the procedure</td>
									<td align="center">17 (50.0)</td>
								</tr>
								<tr>
									<td>GCE indications</td>
									<td> </td>
								</tr>
								<tr>
									<td>Proximal tortuosity</td>
									<td align="center">22 (64.7)</td>
								</tr>
								<tr>
									<td>Vessel angulation</td>
									<td align="center">29 (85.3)</td>
								</tr>
								<tr>
									<td>Unfavorable coronary ostium position</td>
									<td align="center">8 (23.5)</td>
								</tr>
								<tr>
									<td>IVUS</td>
									<td align="center">6 (17.6)</td>
								</tr>
								<tr>
									<td>DES, n</td>
									<td align="center">1,6 [1-3]</td>
								</tr>
								<tr>
									<td>Lesion length</td>
									<td align="center">34 [24-47]</td>
								</tr>
								<tr>
									<td>Contrast medium volume</td>
									<td align="center">200 [150-250]</td>
								</tr>
								<tr>
									<td>Microcatheter use</td>
									<td align="center">4 (11.8)</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN3">
								<p>Values are expressed as n (%) or median [range].</p>
							</fn>
							<fn id="TFN4">
								<p>CTO: chronic total occlusion; GCE: guide catheter extensions; IVUS: intravascular ultrasound; DES: drug eluting stent.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
			<sec>
				<title>Procedural and in-hospital outcomes</title>
				<p>The overall device success was achieved in 88% of procedures and procedural success in 91%. Acute complications were one coronary dissection and three side branch occlusions; no cardiac tamponade or coronary perforations were reported. During the in-hospital follow-up, there was only one minor bleeding and no deaths, strokes or MI were reported. <xref ref-type="table" rid="t3">Table 3</xref> summarizes procedural and in-hospital outcomes.</p>
				<p>
					<table-wrap id="t3">
						<label>Table 3</label>
						<caption>
							<title>Procedural results, complications and in-hospital clinical outcomes of the study patients</title>
						</caption>
						<table frame="hsides" rules="groups">
							<colgroup width="50%">
								<col/>
								<col/>
							</colgroup>
							<thead>
								<tr>
									<th align="left">Procedural results</th>
									<th align="left" style="font-weight:normal"> </th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td>Device success</td>
									<td align="center">30 (88.2)</td>
								</tr>
								<tr>
									<td>Procedural <italic>s</italic>uccess</td>
									<td align="center">31 (91.2)</td>
								</tr>
								<tr>
									<td>Coronary perforation</td>
									<td align="center">0</td>
								</tr>
								<tr>
									<td>Unresolved dissection</td>
									<td align="center">1 (2.9)</td>
								</tr>
								<tr>
									<td>Side branch occlusion</td>
									<td align="center">3 (8.8)</td>
								</tr>
								<tr>
									<td>Bleeding</td>
									<td> </td>
								</tr>
								<tr>
									<td>No</td>
									<td align="center">2,470 (97.6)</td>
								</tr>
								<tr>
									<td>Minor</td>
									<td align="center">1 (2.9)</td>
								</tr>
								<tr>
									<td>Major</td>
									<td align="center">0</td>
								</tr>
								<tr>
									<td>Death</td>
									<td align="center">0</td>
								</tr>
								<tr>
									<td>Stroke</td>
									<td align="center">0</td>
								</tr>
								<tr>
									<td>MI</td>
									<td align="center">0</td>
								</tr>
								<tr>
									<td>MACCE</td>
									<td align="center">0</td>
								</tr>
							</tbody>
						</table>
						<table-wrap-foot>
							<fn id="TFN5">
								<p>Values are expressed as n (%).</p>
							</fn>
							<fn id="TFN6">
								<p>MI: myocardial infarction; MACCE: major cardiac and cerebrovascular events.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>The main findings of our study are that patients undergoing complex PCI with the Expressman™ GCE experienced a high rate of procedural and device success, with low rates of complications. Guide catheter extensions have been widely used in contemporary Interventional Cardiology practice given their easiness of use and safety. Nowadays, they are considered a key device in a Catheterization Laboratory for management of tortuous vessels, challenging anatomies and uncrossable lesions during PCI.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> Expressman™ is a new generation device with excellent deliverability, side holes that allow antegrade blood flow to mitigate GCE-induced coronary ischemia, and a longer exchange segment that positions the transition zone outside the aortic arch and enable equipment delivery (<xref ref-type="fig" rid="f01">Figure 1</xref>). The study results with a small number of patients are encouraging, but further studies with large samples and comparison with different GCE models are needed.</p>
			<p>
				<fig id="f01">
					<label>Figure 1</label>
					<caption>
						<title>The Expressman Guide Catheter Extension.</title>
					</caption>
					<graphic xlink:href="2595-4350-jotci-31-eA20230009-gf01.tif"/>
					<attrib><bold>Source:</bold> courtesy of APT Medical.</attrib>
				</fig>
			</p>
			<p>Liao et al. have recently reported the performance of the Expressman™ GCE in a sample of more than 600 patients, in which a smaller version (tapered 4F) was compared with a 5F GCE.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> The authors observed favorable clinical results with both devices, but the 4F version was able to better deeply intubate the target coronary vessel. In the present study, the Expressman™ was offered on demand to operators in case they required such a device. This unique methodological aspect has translated into a selection of a very particular sample of patients, in whom many adverse clinical and angiographic characteristics were common, such as diabetes mellitus, previous heart disease, coronary tortuosity, angulation, calcification and others. Despite not having a control group, the prevalence of such characteristics was much higher than those reported on contemporary studies of PCI in daily practice. The high success rate reported in this context is of note and it can be fair to assume that many cases could not have been done if the GCE was not available, since many operators had requested it as a last resort to successfully perform in the case.</p>
			<p>Complication rates with GCE use in general PCI are generally less than 2% and include dissections, coronary ischemia due to deep intubation and gear damage when passing through the transition, or because of the small lumen of the device.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Due to its unique design, the Expressman™ GCE device may reduce two of these potential limitations – coronary ischemia and equipment damage – but direct comparisons amongst different GCEs models are not available yet. It is also important to consider that half of the study participants had presented with ACS, a situation where a higher rate of complications is generally expected.</p>
			<p>Our study had some limitations. First, this was an observational study with a descriptive purpose of the first group of patients being treated with the Expressman™ in Brazil, and we did not include a control group for comparison. Second, this study had a small number of patients, and the findings may change with a larger sample. Third, the presence of selection bias cannot be excluded as there was no standardization for case selection.</p>
		</sec>
		<sec sec-type="conclusions">
			<title>CONCLUSION</title>
			<p>In a small sample of high-risk patients submitted to complex percutaneous coronary interventions in a reference center, the Expressman™ guide catheter extensions were safely used, with a high rate of procedural and device success, and low rates of complications. Its use as a bailout technique in complex anatomies allowed procedural success in the vast majority of otherwise untreatable patients. These results warrant further investigation with a larger sample of patients, randomized design and comparison with other guide catheter extensions models available for clinical use.</p>
		</sec>
	</body>
	<back>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. de Man FH, Tandjung K, Hartmann M, van Houwelingen KG, Stoel MG, Louwerenburg HW, et al. Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry. EuroIntervention. 2012;8(3):336-44. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4244/EIJV8I3A52">https://doi.org/10.4244/EIJV8I3A52</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>de Man</surname>
							<given-names>FH</given-names>
						</name>
						<name>
							<surname>Tandjung</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Hartmann</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>van Houwelingen</surname>
							<given-names>KG</given-names>
						</name>
						<name>
							<surname>Stoel</surname>
							<given-names>MG</given-names>
						</name>
						<name>
							<surname>Louwerenburg</surname>
							<given-names>HW</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry</article-title>
					<source>EuroIntervention</source>
					<year>2012</year>
					<volume>8</volume>
					<issue>3</issue>
					<fpage>336</fpage>
					<lpage>344</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4244/EIJV8I3A52">https://doi.org/10.4244/EIJV8I3A52</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Sharma D, Shah A, Osten M, Ing D, Barolet A, Overgaard CB, et al. Efficacy and safety of the GuideLiner Mother-in-child guide catheter extension in percutaneous coronary intervention. J Interv Cardiol. 2017;30(1):46-55. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/joic.12354">https://doi.org/10.1111/joic.12354</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Sharma</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Shah</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Osten</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Ing</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Barolet</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Overgaard</surname>
							<given-names>CB</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Efficacy and safety of the GuideLiner Mother-in-child guide catheter extension in percutaneous coronary intervention</article-title>
					<source>J Interv Cardiol</source>
					<year>2017</year>
					<volume>30</volume>
					<issue>1</issue>
					<fpage>46</fpage>
					<lpage>55</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/joic.12354">https://doi.org/10.1111/joic.12354</ext-link>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Duong T, Christopoulos G, Luna M, Christakopoulos G, Master RG, Rangan BV, et al. Frequency, indications, and outcomes of guide catheter extension use in percutaneous coronary intervention. J Invasive Cardiol. 2015;27(10):E211-5. PMID: 26429852.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Duong</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Christopoulos</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Luna</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Christakopoulos</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Master</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Rangan</surname>
							<given-names>BV</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Frequency, indications, and outcomes of guide catheter extension use in percutaneous coronary intervention</article-title>
					<source>J Invasive Cardiol</source>
					<year>2015</year>
					<volume>27</volume>
					<issue>10</issue>
					<fpage>E211</fpage>
					<lpage>E215</lpage>
					<comment>PMID: 26429852</comment>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Mody R, Dash D, Mody B, Saholi A. Guide extension catheter-facilitated reverse controlled antegrade and retrograde tracking for retrograde recanalization of chronic total occlusion. Case Rep Cardiol. 2021;2021:6690452. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2021/6690452">https://doi.org/10.1155/2021/6690452</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mody</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Dash</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Mody</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Saholi</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Guide extension catheter-facilitated reverse controlled antegrade and retrograde tracking for retrograde recanalization of chronic total occlusion</article-title>
					<source>Case Rep Cardiol</source>
					<year>2021</year>
					<volume>2021</volume>
					<size units="pages">6690452</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1155/2021/6690452">https://doi.org/10.1155/2021/6690452</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Liao J, Wu R, Ma Y, Zhang M, Chen Y, Yao K, et al. A novel tapered guide extension catheter facilitated successful completion of complex percutaneous coronary intervention. Eur J Med Res. 2023;28(1):101. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40001-023-01067-w">https://doi.org/10.1186/s40001-023-01067-w</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Liao</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Ma</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Zhang</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Yao</surname>
							<given-names>K</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>A novel tapered guide extension catheter facilitated successful completion of complex percutaneous coronary intervention</article-title>
					<source>Eur J Med Res</source>
					<year>2023</year>
					<volume>28</volume>
					<issue>1</issue>
					<size units="pages">101</size>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40001-023-01067-w">https://doi.org/10.1186/s40001-023-01067-w</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, et al.; Chronic Total Occlusion Academic Research Consortium. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC Consensus Recommendations. Circulation. 2021;143(5):479-500. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.120.046754">https://doi.org/10.1161/CIRCULATIONAHA.120.046754</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ybarra</surname>
							<given-names>LF</given-names>
						</name>
						<name>
							<surname>Rinfret</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Brilakis</surname>
							<given-names>ES</given-names>
						</name>
						<name>
							<surname>Karmpaliotis</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Azzalini</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Grantham</surname>
							<given-names>JA</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<person-group person-group-type="author">
						<collab>Chronic Total Occlusion Academic Research Consortium</collab>
					</person-group>
					<article-title>Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC Consensus Recommendations</article-title>
					<source>Circulation</source>
					<year>2021</year>
					<volume>143</volume>
					<issue>5</issue>
					<fpage>479</fpage>
					<lpage>500</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.120.046754">https://doi.org/10.1161/CIRCULATIONAHA.120.046754</ext-link>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Christopoulos G, Kandzari DE, Yeh RW, Jaffer FA, Karmpaliotis D, Wyman MR, et al. Development and validation of a novel scoring system for predicting technical success of chronic total occlusion percutaneous coronary interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. JACC Cardiovasc Interv. 2016;9(1):1-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcin.2015.09.022">https://doi.org/10.1016/j.jcin.2015.09.022</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Christopoulos</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Kandzari</surname>
							<given-names>DE</given-names>
						</name>
						<name>
							<surname>Yeh</surname>
							<given-names>RW</given-names>
						</name>
						<name>
							<surname>Jaffer</surname>
							<given-names>FA</given-names>
						</name>
						<name>
							<surname>Karmpaliotis</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Wyman</surname>
							<given-names>MR</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Development and validation of a novel scoring system for predicting technical success of chronic total occlusion percutaneous coronary interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score</article-title>
					<source>JACC Cardiovasc Interv</source>
					<year>2016</year>
					<volume>9</volume>
					<issue>1</issue>
					<fpage>1</fpage>
					<lpage>9</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcin.2015.09.022">https://doi.org/10.1016/j.jcin.2015.09.022</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-64. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2018.08.1038">https://doi.org/10.1016/j.jacc.2018.08.1038</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Thygesen</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Alpert</surname>
							<given-names>JS</given-names>
						</name>
						<name>
							<surname>Jaffe</surname>
							<given-names>AS</given-names>
						</name>
						<name>
							<surname>Chaitman</surname>
							<given-names>BR</given-names>
						</name>
						<name>
							<surname>Bax</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Morrow</surname>
							<given-names>DA</given-names>
						</name>
						<etal>et al</etal>
						<collab>Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction</collab>
					</person-group>
					<article-title>Fourth Universal Definition of Myocardial Infarction (2018)</article-title>
					<source>J Am Coll Cardiol</source>
					<year>2018</year>
					<volume>72</volume>
					<issue>18</issue>
					<fpage>2231</fpage>
					<lpage>2264</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2018.08.1038">https://doi.org/10.1016/j.jacc.2018.08.1038</ext-link>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-47. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.110.009449">https://doi.org/10.1161/CIRCULATIONAHA.110.009449</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mehran</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Rao</surname>
							<given-names>SV</given-names>
						</name>
						<name>
							<surname>Bhatt</surname>
							<given-names>DL</given-names>
						</name>
						<name>
							<surname>Gibson</surname>
							<given-names>CM</given-names>
						</name>
						<name>
							<surname>Caixeta</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Eikelboom</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium</article-title>
					<source>Circulation</source>
					<year>2011</year>
					<volume>123</volume>
					<issue>23</issue>
					<fpage>2736</fpage>
					<lpage>2747</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.110.009449">https://doi.org/10.1161/CIRCULATIONAHA.110.009449</ext-link>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Ellis SG, Ajluni S, Arnold AZ, Popma JJ, Bittl JA, Eigler NL, et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation. 1994;90(6):2725-30. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.cir.90.6.2725">https://doi.org/10.1161/01.cir.90.6.2725</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ellis</surname>
							<given-names>SG</given-names>
						</name>
						<name>
							<surname>Ajluni</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Arnold</surname>
							<given-names>AZ</given-names>
						</name>
						<name>
							<surname>Popma</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Bittl</surname>
							<given-names>JA</given-names>
						</name>
						<name>
							<surname>Eigler</surname>
							<given-names>NL</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Increased coronary perforation in the new device era. Incidence, classification, management, and outcome</article-title>
					<source>Circulation</source>
					<year>1994</year>
					<volume>90</volume>
					<issue>6</issue>
					<fpage>2725</fpage>
					<lpage>2730</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.cir.90.6.2725">https://doi.org/10.1161/01.cir.90.6.2725</ext-link>
					</comment>
				</element-citation>
			</ref>
		</ref-list>
	</back>
	<sub-article article-type="translation" id="TRpt" xml:lang="pt">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>ARTIGO ORIGINAL</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Experiência inicial com a extensão de cateter-guia Expressman™ em um centro terciário de cardiologia de alto volume</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-3383-5365</contrib-id>
					<name>
						<surname>Silveira</surname>
						<given-names>Eduardo</given-names>
					</name>
					<role>Concepção e desenho do estudo</role>
					<role>coleta dos dados</role>
					<role>composição do texto</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4198-2621</contrib-id>
					<name>
						<surname>Slaviero</surname>
						<given-names>João Vitor</given-names>
					</name>
					<role>Concepção e desenho do estudo</role>
					<role>coleta dos dados</role>
					<role>composição do texto</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9620-2429</contrib-id>
					<name>
						<surname>Azmus</surname>
						<given-names>Alexandre</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0002-1675-9911</contrib-id>
					<name>
						<surname>Moraes</surname>
						<given-names>Cláudio Vasques de</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3799-098X</contrib-id>
					<name>
						<surname>Teixeira</surname>
						<given-names>Julio Vinicius</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9674-8528</contrib-id>
					<name>
						<surname>Leite</surname>
						<given-names>Rogério Sarmento</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0006-8686-4476</contrib-id>
					<name>
						<surname>Manica</surname>
						<given-names>André</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9698-1787</contrib-id>
					<name>
						<surname>Gomes</surname>
						<given-names>Henrique</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<surname>Moraes</surname>
						<given-names>Claudio</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0009-0001-7099-830X</contrib-id>
					<name>
						<surname>Azevedo</surname>
						<given-names>Eduardo</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0415-1020</contrib-id>
					<name>
						<surname>Teixeira</surname>
						<given-names>Julia Kurtz</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5018-9989</contrib-id>
					<name>
						<surname>Fuchs</surname>
						<given-names>Felipe</given-names>
					</name>
					<role>aprovação da versão final a ser publicada</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-9027-0623</contrib-id>
					<name>
						<surname>Piccaro</surname>
						<given-names>Pedro</given-names>
					</name>
					<role>Concepção e desenho do estudo</role>
					<role>interpretação dos dados</role>
					<role>composição do texto</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-3192-8835</contrib-id>
					<name>
						<surname>Quadros</surname>
						<given-names>Alexandre Schaan de</given-names>
					</name>
					<role>Concepção e desenho do estudo</role>
					<role>interpretação dos dados</role>
					<role>composição do texto</role>
					<xref ref-type="aff" rid="aff1002"><sup>1</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1002">
				<label>1</label>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brasil.</institution>
			</aff>
			<author-notes>
				<corresp id="c01002"><bold>Autor correspondente:</bold> Alexandre Quadros. Avenida Princesa Isabel, 395 − Santana. CEP: 90620-001 − Porto Alegre, RS, Brasil. E-mail: consult.asq@gmail.com </corresp>
				<fn fn-type="conflict">
					<p>DECLARAÇÃO DE CONFLITOS DE INTERESSE</p>
					<p>Este estudo foi financiado pela APT Medical.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>RESUMO</title>
				<sec>
					<title>Introdução</title>
					<p> As extensões de cateter-guia fornecem maior suporte em intervenções coronárias percutâneas complexas. O Expressman™ é uma nova extensão de cateter-guia, e nosso objetivo foi avaliar o impacto de seu uso no sucesso do procedimento e nas complicações ocorridas em um centro de referência de alto volume.</p>
				</sec>
				<sec>
					<title>Métodos</title>
					<p> Analisamos os dados de todos os procedimentos consecutivos em que foi usada uma extensão de cateter-guia Expressman™. A decisão de usar uma extensão de cateter-guia ficou a critério do operador. O sucesso do dispositivo foi definido como o posicionamento bem-sucedido da extensão de cateter-guia dentro do vaso coronário, e o sucesso do procedimento foi definido como &lt;20% de estenose residual e fluxo TIMI 3, sem perda significativa de ramos laterais. Eventos adversos cardíacos e cerebrovasculares maiores foram definidos como a combinação morte por todas as causas, infarto do miocárdio, revascularização do vaso-alvo e acidente vascular cerebral.</p>
				</sec>
				<sec>
					<title>Resultados</title>
					<p> Foram incluídos 34 procedimentos entre abril de 2022 e janeiro de 2023. A maioria dos pacientes era do sexo masculino (59%), e a média de idade foi 66,5 anos. O uso da extensão de cateter-guia não foi planejado antes do procedimento em 17 procedimentos (50%). Os motivos mais comuns para o uso da extensão de cateter-guia foram angulação ou tortuosidade do vaso-alvo e posição desfavorável do óstio coronário. O sucesso do dispositivo foi obtido em 88% e o da revascularização, em 91%. Houve três oclusões de ramo lateral. Durante o acompanhamento clínico intra-hospitalar, não ocorreram sangramento e nem eventos adversos cardíacos e cerebrovasculares maiores.</p>
				</sec>
				<sec>
					<title>Conclusão</title>
					<p> O sucesso do dispositivo e do procedimento foi alto, e a taxa de complicações foi baixa. O uso da extensão de cateter-guia como técnica de resgate em anatomias complexas permitiu o sucesso do procedimento na maioria dos pacientes que, de outro modo, não poderiam ser tratados.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<kwd>Intervenção coronária percutânea</kwd>
				<kwd>Cateteres cardíacos</kwd>
				<kwd>Doença da artéria coronária</kwd>
				<kwd>Desenho de equipamento</kwd>
				<kwd>Resultado do tratamento</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>INTRODUÇÃO</title>
				<p>Os pacientes submetidos a intervenções coronárias percutâneas (ICP) complexas apresentam com maior frequência características clínicas e angiográficas adversas, como idade avançada, maior tortuosidade dos vasos e calcificação extensa. Para obter o sucesso do procedimento nessas situações complexas, têm sido cada vez mais usadas extensões de cateter-guia (GCE, sigla em inglês para <italic>guide catheter extension</italic>).<sup><xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref></sup> Esses dispositivos permitem um posicionamento profundo dentro da artéria coronária, oferecendo maior suporte para o avanço do fio-guia e do microcateter e melhorando a capacidade de implantação de balões e stents.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> As GCEs também podem permitir a visualização seletiva do vaso e melhorar a estabilidade do cateter-guia. Apesar de todos esses benefícios teóricos e da experiência dos intervencionistas, ainda existem relativamente poucos dados publicados que abordam o uso desses dispositivos. A GCE Expressman™ é uma nova extensão de cateter-guia com orifícios laterais próximos à ponta, projetada para garantir o fluxo sanguíneo anterógrado e diminuir a isquemia coronariana, uma possível complicação da intubação profunda com esses dispositivos.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Além disso, possui um longo segmento de troca (35cm), para facilitar a implantação do stent com menos resistência.</p>
				<p>O objetivo do presente estudo foi determinar o impacto da GCE Expressman™ no sucesso do procedimento, nas taxas de complicações e nos resultados hospitalares em pacientes submetidos à ICP complexa.</p>
			</sec>
			<sec sec-type="methods">
				<title>MÉTODOS</title>
				<sec>
					<title>População do estudo</title>
					<p>Foram considerados para inclusão todos os procedimentos consecutivos com indicação de uso de GCE no período de abril de 2022 a janeiro de 2023. Os critérios de inclusão foram idade superior a 18 anos e consentimento informado por escrito. Não houve critérios de exclusão clínicos ou angiográficos, e a decisão de se usar um GCE ficou a critério do operador.</p>
				</sec>
				<sec>
					<title>Coleta de dados</title>
					<p>Os investigadores adicionaram dados de ICP a uma plataforma <italic>on-line</italic> disponível via <italic>Research Electronic Data Capture</italic> (REDCap). Todos os investigadores receberam instruções padronizadas para a entrada de dados no REDCap, além de informações clínicas, angiográficas e dos procedimentos; resultados clínicos pós-procedimentos foram coletados nessa mesma plataforma.</p>
				</sec>
				<sec>
					<title>Definições</title>
					<p>O sucesso técnico da ICP foi definido como uma revascularização bem-sucedida dentro do segmento tratado e a restauração do fluxo <italic>Thrombolysis In Myocardial Infarction</italic> (TIMI) 3, com &lt;20% de estenose residual e sem oclusão significativa de ramo lateral.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Definiu-se ramo lateral significativo como aquele que supre o ventrículo esquerdo com 1,5mm de diâmetro ou maior. A tortuosidade proximal foi definida como leve (até uma curva com 70°), moderada (duas curvas com mais de 70° ou uma com 90°) ou grave (mais de duas curvas com 70° ou mais de uma curva com 90°).<sup><xref ref-type="bibr" rid="B7">7</xref></sup> O desfecho positivo do procedimento foi definido como obtenção de sucesso técnico sem eventos cardíacos e cerebrovasculares adversos maiores (ECCAM) intra-hospitalares, e o sucesso do dispositivo foi definido como o posicionamento bem-sucedido da GCE dentro do vaso coronário, de modo a obter o uso pretendido pelo operador.</p>
				</sec>
				<sec>
					<title>Desfechos</title>
					<p>O desfecho primário do estudo foi o sucesso da ICP-índice. Os desfechos secundários foram ECCAM intra-hospitalar e complicações do procedimento. Os principais ECCAM incluíram morte por todas as causas, infarto do miocárdio (IM) e acidente vascular cerebral (AVC). O IM foi definido usando a quarta definição universal de IM (tipo 4a).<sup><xref ref-type="bibr" rid="B8">8</xref></sup> O AVC foi definido como um novo défice neurológico focal de início súbito de causa presumivelmente cerebrovascular irreversível (ou resultando em morte) dentro de 24 horas e não associado a qualquer outra causa facilmente identificável.</p>
					<p>As complicações do procedimento incluíram sangramento maior, perfuração coronária, tamponamento cardíaco e revascularização urgente com ICP ou cirurgia de revascularização miocárdica (CRM). Sangramento maior foi definido como qualquer sangramento que causasse redução na hemoglobina &gt;3g/dL e sangramento que exigisse transfusão ou intervenção cirúrgica.<sup><xref ref-type="bibr" rid="B9">9</xref></sup> A perfuração coronária foi relatada e classificada de acordo com a classificação de Ellis.<sup><xref ref-type="bibr" rid="B10">10</xref></sup></p>
				</sec>
				<sec>
					<title>Análise estatística</title>
					<p>Os dados categóricos foram apresentados como números e porcentagens, ao passo que as variáveis contínuas foram apresentadas como média ± desvio-padrão ou mediana [intervalo]. Por se tratar de um estudo observacional sem grupo controle, nenhuma análise estatística adicional foi apresentada.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>RESULTADOS</title>
				<sec>
					<title>Características clínicas basais</title>
					<p>De abril de 2022 a janeiro de 2023, 34 procedimentos consecutivos com a GCE Expressman™ foram incluídos no banco de dados. A média de idade foi 65 anos, metade dos pacientes apresentava diabetes melito, e a maioria apresentava dislipidemia e hipertensão (<xref ref-type="table" rid="t1002">Tabela 1</xref>). Metade dos pacientes relatou história pregressa de IM e ICP, e o diagnóstico de insuficiência cardíaca esteve presente em um em cada dez indivíduos. A maioria dos procedimentos foi realizada no cenário de síndrome coronariana aguda (SCA).</p>
					<p>
						<table-wrap id="t1002">
							<label>Tabela 1</label>
							<caption>
								<title>Características iniciais dos pacientes do estudo</title>
							</caption>
							<table frame="hsides" rules="groups">
								<colgroup width="50%">
									<col/>
									<col/>
								</colgroup>
								<thead>
									<tr>
										<th align="left">Características clínicas </th>
										<th align="left" style="font-weight:normal"> </th>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td>Idade</td>
										<td align="center">65±9,4</td>
									</tr>
									<tr>
										<td>Sexo masculino</td>
										<td align="center">20 (58,8)</td>
									</tr>
									<tr>
										<td>IMC</td>
										<td align="center">27,4 [26,2-29,4]</td>
									</tr>
									<tr>
										<td>Hipertensão</td>
										<td align="center">33 (97,1)</td>
									</tr>
									<tr>
										<td>Diabetes melito</td>
										<td align="center">16 (47,1)</td>
									</tr>
									<tr>
										<td>Dislipidemia</td>
										<td align="center">32 (94,1)</td>
									</tr>
									<tr>
										<td>DVP</td>
										<td align="center">4 (11,8)</td>
									</tr>
									<tr>
										<td>História familiar de DAC</td>
										<td align="center">1 (2,9)</td>
									</tr>
									<tr>
										<td>Tabagismo (atual)</td>
										<td align="center">14 (41,2)</td>
									</tr>
									<tr>
										<td>IM prévio</td>
										<td align="center">16 (47,1)</td>
									</tr>
									<tr>
										<td>ICP prévia</td>
										<td align="center">16 (47,1)</td>
									</tr>
									<tr>
										<td>CRM prévia</td>
										<td align="center">6 (17,6)</td>
									</tr>
									<tr>
										<td>AVC prévio</td>
										<td align="center">2 (5,9)</td>
									</tr>
									<tr>
										<td>Insuficiência cardíaca</td>
										<td align="center">4 (11,8)</td>
									</tr>
									<tr>
										<td>Doença renal crônica</td>
										<td align="center">2 (5,9)</td>
									</tr>
									<tr>
										<td>SCA</td>
										<td align="center">28 (82,4)</td>
									</tr>
								</tbody>
							</table>
							<table-wrap-foot>
								<fn id="TFN1002">
									<p>Resultados expressos como média ± desvio-padrão, n (%) ou mediana [intervalo].</p>
								</fn>
								<fn id="TFN2002">
									<p>IMC: índice de massa corporal; DVP: doença vascular periférica; DAC: doença arterial coronariana; IM: infarto do miocárdio; ICP: intervenção coronária percutânea; CRM: cirurgia de revascularização miocárdica; SCA: síndrome coronariana aguda.</p>
								</fn>
							</table-wrap-foot>
						</table-wrap>
					</p>
					<p>A <xref ref-type="table" rid="t2002">tabela 2</xref> mostra as características angiográficas e do procedimento dos pacientes do estudo. As artérias descendente anterior e coronária direita foram os vasos-alvo mais frequentes, e a maioria dos procedimentos foi realizada via artéria radial. A oclusão crônica como lesão-alvo ocorreu em 12% dos casos, e apenas um procedimento foi feito com o uso adjuvante de aterectomia rotacional. Em metade dos casos, o uso da GCE foi planejado antecipadamente; nos demais, a GCE foi utilizada como resgate após o operador enfrentar problemas técnicos para concluir o procedimento. As principais razões para o uso de GCE foram angulação do vaso, tortuosidade do vaso proximal e posição desfavorável do óstio coronariano. Microcateteres e ultrassonografia intravascular (IVUS) foram raramente usados.</p>
					<p>
						<table-wrap id="t2002">
							<label>Tabela 2</label>
							<caption>
								<title>Características angiográficas e do procedimento dos pacientes do estudo</title>
							</caption>
							<table frame="hsides" rules="groups">
								<colgroup width="50%">
									<col/>
									<col/>
								</colgroup>
								<thead>
									<tr>
										<th align="left">Características do procedimento </th>
										<th align="left" style="font-weight:normal"> </th>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td>Acesso radial</td>
										<td align="center">21 (61,8)</td>
									</tr>
									<tr>
										<td>Aterectomia rotacional</td>
										<td align="center">1 (2,9)</td>
									</tr>
									<tr>
										<td>Vaso-alvo</td>
										<td> </td>
									</tr>
									<tr>
										<td>Tronco da artéria coronária esquerda</td>
										<td align="center">1 (2,9)</td>
									</tr>
									<tr>
										<td>Artéria descendente anterior</td>
										<td align="center">12 (35,3)</td>
									</tr>
									<tr>
										<td>Artéria circunflexa</td>
										<td align="center">8 (23,5)</td>
									</tr>
									<tr>
										<td>Artéria coronária direita</td>
										<td align="center">12 (35,3)</td>
									</tr>
									<tr>
										<td>OC</td>
										<td align="center">4 (11,8)</td>
									</tr>
									<tr>
										<td>Uso de GCE planejado antes do procedimento</td>
										<td align="center">17 (50,0)</td>
									</tr>
									<tr>
										<td>Indicações para GCE</td>
										<td> </td>
									</tr>
									<tr>
										<td>Tortuosidade proximal</td>
										<td align="center">22 (64,7)</td>
									</tr>
									<tr>
										<td>Angulação do vaso</td>
										<td align="center">29 (85,3)</td>
									</tr>
									<tr>
										<td>Posição desfavorável do óstio coronário</td>
										<td align="center">8 (23,5)</td>
									</tr>
									<tr>
										<td>IVUS</td>
										<td align="center">6 (17,6)</td>
									</tr>
									<tr>
										<td>SF, n</td>
										<td align="center">1,6 [1-3]</td>
									</tr>
									<tr>
										<td>Comprimento da lesão</td>
										<td align="center">34 [24-47]</td>
									</tr>
									<tr>
										<td>Volume de meio de contraste</td>
										<td align="center">200 [150-250]</td>
									</tr>
									<tr>
										<td>Uso de microcateter</td>
										<td align="center">4 (11,8)</td>
									</tr>
								</tbody>
							</table>
							<table-wrap-foot>
								<fn id="TFN3002">
									<p>Os valores são expressos como n (%) ou mediana [intervalo].</p>
								</fn>
								<fn id="TFN4002">
									<p>OC: oclusão crônica; GCE: extensões de cateter-guia; IVUS: ultrassonografia intravascular; SF: stent farmacológico.</p>
								</fn>
							</table-wrap-foot>
						</table-wrap>
					</p>
				</sec>
				<sec>
					<title>Resultados dos procedimentos e intra-hospitalares</title>
					<p>O sucesso geral do dispositivo foi alcançado em 88% dos procedimentos e o sucesso do procedimento, em 91%. As complicações agudas foram uma dissecção coronária e três oclusões de ramo lateral; não houve relatos de tamponamento cardíaco ou perfurações coronárias. Durante o seguimento intra-hospitalar, houve apenas um sangramento menor e não foram relatados mortes, AVC ou IM. A <xref ref-type="table" rid="t3002">tabela 3</xref> resume os resultados dos procedimentos e intra-hospitalares.</p>
					<p>
						<table-wrap id="t3002">
							<label>Tabela 3</label>
							<caption>
								<title>Resultados dos procedimentos, complicações e resultados clínicos intra-hospitalares dos pacientes do estudo</title>
							</caption>
							<table frame="hsides" rules="groups">
								<colgroup width="50%">
									<col/>
									<col/>
								</colgroup>
								<thead>
									<tr>
										<th align="left">Resultados procedurais</th>
										<th align="left" style="font-weight:normal"> </th>
									</tr>
								</thead>
								<tbody>
									<tr>
										<td>Sucesso do dispositivo</td>
										<td align="center">30 (88,2)</td>
									</tr>
									<tr>
										<td>Sucesso do procedimento</td>
										<td align="center">31 (91,2)</td>
									</tr>
									<tr>
										<td>Perfuração coronária</td>
										<td align="center">0</td>
									</tr>
									<tr>
										<td>Dissecção não resolvida</td>
										<td align="center">1 (2,9)</td>
									</tr>
									<tr>
										<td>Oclusão de ramo lateral</td>
										<td align="center">3 (8,8)</td>
									</tr>
									<tr>
										<td>Sangramento</td>
										<td> </td>
									</tr>
									<tr>
										<td>Ausente</td>
										<td align="center">2.470 (97,6)</td>
									</tr>
									<tr>
										<td>Menor</td>
										<td align="center">1 (2,9)</td>
									</tr>
									<tr>
										<td>Maior</td>
										<td align="center">0</td>
									</tr>
									<tr>
										<td>Morte</td>
										<td align="center">0</td>
									</tr>
									<tr>
										<td>AVC</td>
										<td align="center">0</td>
									</tr>
									<tr>
										<td>IM</td>
										<td align="center">0</td>
									</tr>
									<tr>
										<td>ECCAM</td>
										<td align="center">0</td>
									</tr>
								</tbody>
							</table>
							<table-wrap-foot>
								<fn id="TFN5002">
									<p>Os valores são expressos como n (%).</p>
								</fn>
								<fn id="TFN6002">
									<p>AVC: acidente vascular cerebral; IM: infarto do miocárdio; ECCAM: eventos cardíacos e cerebrovasculares maiores.</p>
								</fn>
							</table-wrap-foot>
						</table-wrap>
					</p>
				</sec>
			</sec>
			<sec sec-type="discussion">
				<title>DISCUSSÃO</title>
				<p>Os principais achados de nosso estudo foram que os pacientes submetidos à ICP complexa com a GCE Expressman™ tiveram alta taxa de sucesso do procedimento e do dispositivo, com baixas taxas de complicações. As GCEs têm sido amplamente utilizadas na prática da Cardiologia Intervencionista contemporânea devido à sua facilidade de uso e à sua segurança. Atualmente, são considerados um dispositivo-chave do Setor de Hemodinâmica no manejo de vasos tortuosos, anatomias desafiadoras e lesões intransponíveis durante a ICP.<sup><xref ref-type="bibr" rid="B2">2</xref></sup> A Expressman™ é um dispositivo de nova geração com excelente capacidade de implantação, orifícios laterais que permitem fluxo sanguíneo anterógrado para atenuar a isquemia coronariana induzida pela GCE e um segmento de troca mais longo, que posiciona a zona de transição fora do arco aórtico e permite a implantação do equipamento (<xref ref-type="fig" rid="f01002">Figura 1</xref>). Os resultados do estudo com um pequeno número de pacientes são animadores, mas são necessários mais trabalhos com grandes amostras e comparação com diferentes modelos de GCE.</p>
				<p>
					<fig id="f01002">
						<label>Figura 1</label>
						<caption>
							<title>Extensão de cateter-guia Expressman™.</title>
						</caption>
						<graphic xlink:href="2595-4350-jotci-31-eA20230009-gf01-pt.tif"/>
						<attrib><bold>Fonte:</bold> cortesia da APT Medical.</attrib>
					</fig>
				</p>
				<p>Liao et al. relataram recentemente o desempenho da GCE Expressman™ em amostra de mais de 600 pacientes, em que uma versão menor (4F de ponta afunilada) foi comparada com uma GCE 5F.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> Os autores observaram resultados clínicos favoráveis com ambos os dispositivos, mas a versão 4F foi melhor de intubar profundamente no vaso coronário-alvo. No presente estudo, a Expressman™ foi oferecida sob demanda aos operadores, caso necessitassem do dispositivo. Esse aspecto metodológico singular se traduziu na seleção de uma amostra muito particular de doentes, em que muitas características clínicas e angiográficas adversas eram comuns, como diabetes melito, doença cardíaca prévia, tortuosidade coronária, angulação, calcificação e outras. Apesar de não haver grupo controle, a prevalência de tais características foi bem maior do que aquelas relatadas em estudos contemporâneos de ICP na prática diária. A elevada taxa de sucesso relatada nesse contexto é digna de nota, e pode ser justo supor que muitos casos não poderiam ter sido resolvidos se a GCE não estivesse disponível, uma vez que muitos operadores a solicitaram como último recurso para ter um desempenho bem-sucedido no caso.</p>
				<p>As taxas de complicação com o uso de GCE em ICP são geralmente inferiores a 2% e incluem dissecções, isquemia coronária devido à intubação profunda e danos no equipamento ao passar pela transição, ou devido ao pequeno lúmen do dispositivo.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Por seu desenho singular, o dispositivo GCE Expressman™ pode diminuir duas das possíveis limitações – isquemia coronariana e danos ao equipamento –, mas ainda não estão disponíveis comparações diretas entre diferentes modelos de GCEs. Também é importante levar em consideração que metade dos participantes do estudo apresentava SCA, situação em que geralmente se espera maior taxa de complicações.</p>
				<p>Nosso estudo teve algumas limitações. Primeiro, foi um estudo observacional com propósito descritivo do primeiro grupo de pacientes tratados com a Expressman™ no Brasil, e não incluímos um grupo controle para comparação. Em segundo lugar, este estudo teve um pequeno número de pacientes e os achados podem mudar com uma amostra maior. Em terceiro lugar, a presença de viés de seleção não pode ser excluída, pois não houve padronização para a seleção de casos.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>CONCLUSÃO</title>
				<p>Em uma pequena amostra de pacientes de alto risco submetidos a intervenções coronárias percutâneas complexas em um centro de referência, as extensões de cateter-guia Expressman™ foram utilizadas com segurança, com alto índice de sucesso do procedimento e do dispositivo, além de baixo índice de complicações. Seu uso como técnica de resgate em anatomias complexas permitiu o sucesso do procedimento na maioria dos pacientes que, de outro modo, não poderiam ser tratados. Esses resultados justificam uma investigação mais aprofundada, com amostra maior de pacientes; um desenho randomizado e a comparação com outros modelos de extensões de cateter-guia disponíveis para uso clínico.</p>
			</sec>
		</body>
	</sub-article>
</article>